Throughout the 2025 American Society of Hematology annual assembly, held earlier this month in Orlando, Florida, CURE sat down with an professional to debate the idea of minimal residual illness, or MRD, and what it means for sufferers with a number of myeloma.
Dr. Dickran Kazandjian is a professor of medical medication within the Myeloma Institute on the College of Miami Sylvester Complete Most cancers Heart in Florida, and he’s additionally a member of CURE’s advisory board. Kazandjian can also be the affiliate director of the Sylvester Myeloma Institute and assistant director of medical analysis research within the workplace of medical analysis on the Sylvester Myeloma Institute.
Kazandjian was the lead researcher on a medical trial, interim outcomes of which have been introduced on the
Transcript
What does minimal residual illness imply, and why is it an vital idea for sufferers with a number of myeloma to grasp?
Minimal residual illness negativity is an idea that we use to mainly describe how we are able to do away with the very, final remaining cells that, based mostly on extra conventional methods of viewing response, will not be captured. So, what I imply is admittedly the extent of detection or sensitivity. After we say sufferers are MRD unfavorable, we imply on the very least, after taking a look at 100,000 regular cells within the bone marrow, it’s a must to show that not even one in all them is a nasty myeloma cell. And we have made loads of advances, and slowly, we’re even getting to vary the one in 100,000 to 1 in one million.
Transcript has been edited for readability and conciseness.
Reference
- “Antibody Remedy Eradicates Traces of A number of Myeloma in Preliminary Trial,” information launch; https://information.med.miami.edu/ash-2025-immunoplant-phase-2-trial/
For extra information on most cancers updates, analysis and schooling, don’t neglect to
